Background: Diabetes mellitus is not only a chronic metabolic disorder but also an inflammatory one. Antidiabetic drugs are required to address both these entities to reduce the micro- and macro-complications associated with diabetes. Some of the incretin-based drugs have been shown to have decreased inflammatory markers. The studies on inflammatory models are very less.
Aims and Objectives: The aim of this study is to evaluate anti-inflammatory activities of liraglutide, a glucagon-like peptide-1 analog, and teneligliptin, a dipeptidyl peptidase-4 inhibitor in experimental acute and subacute models of inflammation and also to evaluate their interactions with ibuprofen, a standard non-steroidal anti-inflammatory drugs.
Materials and Methods: Carrageenan-induced paw edema to assess edema in acute anti-inflammatory action and cotton pellet-induced granuloma method to assess granuloma dry weight of liraglutide and teneligliptin in rats.
Results: Liraglutide did not show anti-edema and anti-granuloma activity but potentiated the anti-granuloma effect of ibuprofen. Teneligliptin showed only anti-granuloma effect and potentiated both anti-edema and anti-granuloma activities of ibuprofen.
Conclusion: Liraglutide and teneligliptin individually have variable anti-inflammatory activities, and they also have variable ibuprofen potentiating action. They have potentiated the subacute anti-inflammatory of ibuprofen by their anti-granuloma effect.
Key words: Liraglutide; Teneligliptin; Anti-inflammatory Action; Drug Potentiation
|
